市場調查報告書

全球裘馨氏肌肉萎縮症治療藥市場

Duchenne Muscular Dystrophy Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 893737
出版日期 內容資訊 英文 94 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球裘馨氏肌肉萎縮症治療藥市場 Duchenne Muscular Dystrophy Drugs
出版日期: 2019年10月01日內容資訊: 英文 94 Pages
簡介

本報告提供全球裘馨氏肌肉萎縮症治療藥市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊彙整。

第1章 調查方法

第2章 摘要整理

  • 市場概要
    • 裘馨氏肌肉萎縮症治療藥市場顯示堅固成長的市場
    • 全球競爭企業的市場佔有率
    • 全球市場佔有率方案
    • 各分類市場佔有率
    • 變異抑制
    • 外顯子跳躍
    • 全球市場趨勢
    • 治療概要與近幾年的發展
    • 治療所使用的類固醇
    • 對幼兒Translarna表現有利的結果
    • 比Emflaza皮質類固醇可保存更佳運動功能透過臨床實驗清楚證實
    • 臨床實驗表示 Golodirsen增加患者的抗肌萎縮蛋白產生
    • FDA核准裘馨氏肌肉萎縮症治療用的皮質類固醇Emflaza
  • 主要參與企業
  • 市場趨勢和促進因素
  • 全球市場預測

第3章 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲各國
  • 亞太地區
  • 其他各國

第4章 競爭

  • ACCELERON PHARMA
  • AKASHI THERAPEUTICS
  • BIOMARIN PHARMACEUTICAL
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • JANSSEN PHARMACEUTICALS
  • LEXICON PHARMACEUTICALS
  • 株式會社日本觸媒
  • NOBELPHARMA
  • PTC THERAPEUTICS
  • PFIZER
  • SAREPTA THERAPEUTICS
  • 大鵬藥品工業株式會社

第5章 相關調查

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP11652

Duchenne Muscular Dystrophy Drugs market worldwide is projected to grow by US$4.9 Billion, driven by a compounded growth of 40.5%. Mutation Suppression, one of the segments analyzed and sized in this study, displays the potential to grow at over 39%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$1.9 Billion by the year 2025, Mutation Suppression will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 45% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$141.4 Million to the region's size and clout in the next 5 to 6 years. Over US$226.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Mutation Suppression will reach a market size of US$144.6 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 38.9% over the next couple of years and add approximately US$809.3 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others, Acceleron Pharma, Inc.; Akashi Therapeutics, Inc.; BioMarin Pharmaceutical, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; Nippon Shokubai Co., Ltd.; Nobelpharma Co., Ltd.; Pfizer, Inc.; PTC Therapeutics, Inc.; Sarepta Therapeutics Inc.; Taiho Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit Strong Growth
  • Global Competitor Market Shares
  • Duchenne Muscular Dystrophy Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Global Market Dynamics
  • Treatment Overview and Recent Developments
  • Steroids used for the Treatment of DMD
  • Translarna Exhibits Positive Result in Children with DMD
  • Clinical Trials Depict Emflaza Preserves Motor Function Better than Corticosteroids
  • Trial Shows Golodirsen Increases Dystrophin Production in DMD Patients
  • Casimersen and Golodirsen Exhibits Positive Results in Sarepta's ESSENCE study
  • EXONDYS 51(r) Drug Details
  • FDA Approves Corticosteroid Emflaza for Treating DMD Patients

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Pipeline Analysis
  • Drug Price Details: Exondys51
  • Sarepta's DMD Gene Therapy Trial Update

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: Duchenne Muscular Dystrophy Drugs Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025
  • TABLE 2: Duchenne Muscular Dystrophy Drugs Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017
  • TABLE 3: Duchenne Muscular Dystrophy Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
  • TABLE 4: Mutation Suppression (Segment) World Market by Region/Country in US$ Thousand: 2018 to 2025
  • TABLE 5: Mutation Suppression (Segment) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017
  • TABLE 6: Mutation Suppression (Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 7: Exon Skipping (Segment) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025
  • TABLE 8: Exon Skipping (Segment) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017
  • TABLE 9: Exon Skipping (Segment) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 10: Other Segments (Segment) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025
  • TABLE 11: Other Segments (Segment) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017
  • TABLE 12: Other Segments (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Duchenne Muscular Dystrophy Drugs Market Share (in %) by Company: 2019 & 2025
    • TABLE 13: United States Duchenne Muscular Dystrophy Drugs Market Estimates and Projections in US$ Thousand by Segment: 2018 to 2025
    • TABLE 14: Duchenne Muscular Dystrophy Drugs Market in the United States by Segment: A Historic Review in US$ Thousand for 2009-2017
    • TABLE 15: United States Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • CANADA
    • TABLE 16: Canadian Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025
    • TABLE 17: Canadian Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017
    • TABLE 18: Duchenne Muscular Dystrophy Drugs Market in Canada: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
  • JAPAN
    • TABLE 19: Japanese Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 20: Duchenne Muscular Dystrophy Drugs Market in Japan: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017
    • TABLE 21: Japanese Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • CHINA
    • TABLE 22: Chinese Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 23: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in China in US$ Thousand by Segment: 2009-2017
    • TABLE 24: Chinese Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • EUROPE
    • Market Facts & Figures
    • European Duchenne Muscular Dystrophy Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025
    • Irish Boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) Gains Access to Key, Life-Supporting Drug
    • CHMP Rejects Exondys 51 in Europe
    • TABLE 25: European Duchenne Muscular Dystrophy Drugs Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025
    • TABLE 26: Duchenne Muscular Dystrophy Drugs Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017
    • TABLE 27: European Duchenne Muscular Dystrophy Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 28: European Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025
    • TABLE 29: Duchenne Muscular Dystrophy Drugs Market in Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017
    • TABLE 30: European Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • FRANCE
    • TABLE 31: Duchenne Muscular Dystrophy Drugs Market in France by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025
    • TABLE 32: French Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017
    • TABLE 33: French Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • GERMANY
    • TABLE 34: Duchenne Muscular Dystrophy Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 35: German Duchenne Muscular Dystrophy Drugs Historic Market Analysis in US$ Thousand by Segment: 2009-2017
    • TABLE 36: German Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ITALY
    • TABLE 37: Italian Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 38: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in Italy in US$ Thousand by Segment: 2009-2017
    • TABLE 39: Italian Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED KINGDOM
    • TABLE 40: United Kingdom Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 41: Duchenne Muscular Dystrophy Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017
    • TABLE 42: United Kingdom Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025
    • TABLE 44: Duchenne Muscular Dystrophy Drugs Market in Rest of Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017
    • TABLE 45: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ASIA-PACIFIC
    • TABLE 46: Duchenne Muscular Dystrophy Drugs Market in Asia-Pacific by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025
    • TABLE 47: Asia-Pacific Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017
    • TABLE 48: Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • REST OF WORLD
    • TABLE 49: Rest of World Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025
    • TABLE 50: Rest of World Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017
    • TABLE 51: Duchenne Muscular Dystrophy Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025

IV. COMPETITION

  • ACCELERON PHARMA
  • AKASHI THERAPEUTICS
  • BIOMARIN PHARMACEUTICAL
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • JANSSEN PHARMACEUTICALS
  • LEXICON PHARMACEUTICALS
  • NIPPON SHOKUBAI
  • NOBELPHARMA
  • PTC THERAPEUTICS
  • PFIZER
  • SAREPTA THERAPEUTICS
  • TAIHO PHARMACEUTICAL

V. CURATED RESEARCH

Back to Top